Navigation Links
ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation
Date:4/1/2008

="http://www.istavision.com" target="_new">http://www.istavision.com.

Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements. Without limiting the foregoing, but by way of example, statements contained in this press release related to the completion of the data analysis and discussions with the FDA regarding the Xibrom QD NDA or possible new Xibrom products and the possibility of a label change for the currently marketed 0.09% formulation of Xibrom, bringing a new product to market every 12 to 18 months, and becoming the leading niche ophthalmic pharmaceutical company are forward- looking statements. Except as required by law, ISTA disclaims any intent or obligation to update any forward-looking statements. These forward-looking statements are based on ISTA's expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially. Important factors that could cause actual results to differ from current expectations include, among others: timely and successful implementation of ISTA's strategic initiatives; delays and uncertainties related to ISTA's research and development programs (including the difficulty of predicting the timing or outcome of product development efforts and the FDA or other regulatory agency approval or actions); uncertainties and risks regarding market acceptance of and demand for ISTA's approved products and the impact of competitive products and pricing; uncertainties and risks related to ISTA's ability to properly manage its growth; uncertainties and risks regarding the continued timely performance by ISTA's strategic partners of their respective obligations under existing collaborations and licensing arrangements; uncertainties and risks related to the continued availability of third party sourced products and raw materials on commercially reasonable terms, or at all; uncertai
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
2. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
3. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
4. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
5. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
6. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
7. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
8. VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
9. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
10. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
11. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ), ... sale of patented biopharmaceutical medicine, modernized traditional Chinese medicine ... announced the business and development progress at its Jiangchuan ... the September 2014 JCM application (No. 51268) for the ...
(Date:1/22/2015)... UPI ), a medical device company that ... voiding dysfunctions, today reported financial results for the fiscal ... revenue for the Company,s Urgent ®  PC Neuromodulation System ... record, as compared to $3.9 million in the third ...
(Date:1/22/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced that it ... on Tuesday, Jan. 27, 2015, after the close of the U.S. ... with the investment community at 2 p.m. PT. Participating in the ... and chief executive officer, and other members of Amgen,s senior management ...
Breaking Medicine Technology:TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2
... YORK , June 24 Reportlinker.com announces that a new market research report ... Global Hernia Repair Devices ... http://www.reportlinker.com/p0209282/Global-Hernia-Repair-Devices-Industry.html , ... This report analyzes the Global market for Hernia Repair Devices in US$ Million by the ...
... June 24 Today the United ... (CDC) issued new and important guidelines on the detection ... of tuberculosis (TB). In these landmark guidelines, CDC advises ... now preferred over the 100+-year-old tuberculin skin test (TST) ...
Cached Medicine Technology:Reportlinker Adds Global Hernia Repair Devices Industry 2Reportlinker Adds Global Hernia Repair Devices Industry 3Reportlinker Adds Global Hernia Repair Devices Industry 4Reportlinker Adds Global Hernia Repair Devices Industry 5Reportlinker Adds Global Hernia Repair Devices Industry 6Reportlinker Adds Global Hernia Repair Devices Industry 7Reportlinker Adds Global Hernia Repair Devices Industry 8Reportlinker Adds Global Hernia Repair Devices Industry 9Reportlinker Adds Global Hernia Repair Devices Industry 10New CDC Guidelines Prefer Use of Blood Tests, Including QuantiFERON®-TB, to Diagnose Tuberculosis Infection in Certain Populations 2New CDC Guidelines Prefer Use of Blood Tests, Including QuantiFERON®-TB, to Diagnose Tuberculosis Infection in Certain Populations 3New CDC Guidelines Prefer Use of Blood Tests, Including QuantiFERON®-TB, to Diagnose Tuberculosis Infection in Certain Populations 4New CDC Guidelines Prefer Use of Blood Tests, Including QuantiFERON®-TB, to Diagnose Tuberculosis Infection in Certain Populations 5
(Date:1/22/2015)... 20 years, Dr. David Cruz of Cruz Chiropractic Care ... about every type of injury that can result from car accidents ... years, the team at Doctors on Liens has been ... With the combined breadth of experience between the two, ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television ... 32nd Annual Miami Breast Cancer Conference planned ... (PER®) , shares that “a fast-growing, virulent” cancer in ... had not followed up her clean mammogram with an ...
(Date:1/22/2015)... Calif. (PRWEB) January 22, 2015 ... Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were ... their leadership in advancing biotechnology, biomedical science, medical ... and Olsen each received the “2014 Life Sciences ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and ... to treat specific body parts and muscle groups. , ... to use patented cold therapy machine with the innovative IsoTube ... muscle injuries. IsoComforter has become the industry leader in ...
(Date:1/22/2015)... January 22, 2015 Payday lending practices ... communities and cause financial distress to the states that ... at Howard University’s Center on Race and Wealth. , ... economic activity, payday loans at the same time substantially ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... D.C. Areas of the brain responsible for ... patients who exercised following a medication holiday, say ... say the changes indicate brain functioning is more ... the brains resources is devoted to processing bothersome ...
... SUNDAY, Nov. 13 (HealthDay News) -- When added to standard ... people with "acute coronary syndrome" lower their risk of death, ... Acute coronary syndrome is an umbrella term that includes people ... finding "opens up a new area for treating this very ...
... study has identified a novel gene mutation that appears ... cases of malignant melanoma, the most deadly form of ... gene encoding MITF, a transcription factor that induces the ... in which melanoma originates. While previous research has ...
... A wearable defibrillator can prevent sudden death in people ... the American Heart Association,s Scientific Sessions 2011. , Wearable ... at higher risk for sudden cardiac arrest, including those ... a condition that prevents or delays them from receiving ...
... women with breast cancer have taken the drug tamoxifen, only ... tumors do not respond to the treatment at all, or ... at the University of California, San Francisco (UCSF) have discovered ... way to defeat it. On Sunday, Nov. 13, ...
... (HealthDay News) -- All U.S. children between the ages of ... to new guidelines endorsed by the nation,s leading group of ... guidelines that suggest such testing be done only for children ... blood cholesterol, which is one of the major risk factors ...
Cached Medicine News:Health News:Improved memory efficiency seen after aerobic exercise in fibromyalgia patients 2Health News:Blood Thinner Xarelto Shows Promise for Heart Patients 2Health News:Blood Thinner Xarelto Shows Promise for Heart Patients 3Health News:Blood Thinner Xarelto Shows Promise for Heart Patients 4Health News:Newly identified gene mutation adds to melanoma risk 2Health News:Newly identified gene mutation adds to melanoma risk 3Health News:Wearable defibrillator can prevent death in people with arrhythmias 2Health News:Tamoxifen resistance -- and how to defeat it 2Health News:Tamoxifen resistance -- and how to defeat it 3Health News:Tamoxifen resistance -- and how to defeat it 4Health News:New Guidelines Urge Cholesterol Check for All Kids Ages 9 to 11 2Health News:New Guidelines Urge Cholesterol Check for All Kids Ages 9 to 11 3Health News:New Guidelines Urge Cholesterol Check for All Kids Ages 9 to 11 4
200 L, Bulk, yellow Recommended for 20, 25, 50, 100 and 200 L pipettes. Can also be used with 300 L pipettes when pipetting 200 L or less....
For restriction digests, immuno-precipitations, enzyme assays, TLC spotting and others...
The Finntip 20 is suitable for applications requiring high precision and volumes of 0.2-20 ul. The tips are provided in convenient racks of 384 tips....
10 L, Bulk Recommended for 2, 5, 10 L pipettes....
Medicine Products: